Trials / Completed
CompletedNCT01882504
Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum
An Open-label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma Gangrenosum
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- XOMA (US) LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will evaluate the safety and biologic activity of gevokizumab in subjects in the acute inflammatory phase of pyoderma gangrenosum.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | gevokizumab |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2015-10-01
- Completion
- 2015-10-01
- First posted
- 2013-06-20
- Last updated
- 2016-02-03
Locations
19 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01882504. Inclusion in this directory is not an endorsement.